Cancer-fighting virus shows promise in early clinical trial

July 8, 2007

A virus that has been specifically designed by scientists to be safe to normal tissue but deadly to cancer is showing early promise in a preliminary study, researchers said at the ESMO Conference Lugano (ECLU), Switzerland.

The virus, called NV1020, is a type of herpes simplex virus modified so that it selectively replicates in virus cells, killing them in the process.

“It doesn’t replicate in normal, healthy cells, so our hope is that it will help fight cancers without causing side-effects in the rest of the body,” said Dr. Axel Mescheder, VP Clinical Research & Development, from the Munich-based biotech company MediGene. The study is conducted in seven leading US-cancer centers, with Dr. Tony Reid from the University of California in San Diego, CA as Principal Investigator. Dr. Mescheder presented preliminary safety and efficacy results and a case report from this ongoing clinical trial in patients with colorectal cancer metastatic to the liver at the meeting.

Dr. Mescheder’s poster presentation described the case of a patient whose cancer had spread to 10 different places around the liver and four in the lungs. He was given the virus treatment in four weekly infusions direct into blood stream, followed by two cycles of approved chemotherapy.

Six months after treatment, scans showed the liver masses had nearly disappeared. “The reduction in the tumor masses was really impressive in this patient,” Dr. Mescheder said. “The hepatic masses almost disappeared.”

The patient survived for 12 months after treatment.

“In the current study, the scientists are testing the treatment in patients with colorectal cancer that have not responded to chemotherapy and where the cancer has spread to the liver,” Dr. Mescheder said. “We are hoping to extend overall survival.”

So far, the findings are looking positive. The treatment seems very tolerable for patients and safe. “The results are really quite encouraging at this early stage,” he said.

Almost 40% of patients with colorectal cancer ultimately die from metastatic disease, where the cancer spreads to other parts of the body. Most of the spreading occurs to the liver and 15% of patients have liver metastases at the time of diagnosis.

The latest human results reported today follow testing in the lab and in animals where the virus was shown to be effective at killing colorectal cancer cells and liver cancers.

Source: European Society for Medical Oncology

Explore further: Finding the causes of cancer is the first step to prevention ​

Related Stories

Recommended for you

Gene therapy to fight a blood cancer succeeds in major study

February 28, 2017

An experimental gene therapy that turns a patient's own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single ...

Genetic 'balance' may influence response to cancer treatment

February 28, 2017

Choosing among cancer treatments increasingly involves determining whether tumor cells harbor specific, mutated "oncogenes" that drive abnormal growth and that may also be especially vulnerable or resistant to particular ...

Tanning devices cost US healthcare $343 million a year

February 28, 2017

Tanning devices cost the US $343.1 million a year in medical costs because of the skin cancers their use is associated with, according to a new study published in the Journal of Cancer Policy. In a new study, Dr. Hugh Waters ...

Molecule stops fatal pediatric brain tumor

February 27, 2017

Northwestern Medicine scientists have found a molecule that stops the growth of an aggressive pediatric brain tumor. The tumor is always fatal and primarily strikes children under 10 years old.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.